Role of End-Tidal CO2 During Passive Leg Raising to Predict Fluid Responsiveness in ICU

NCT ID: NCT07304648

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

68 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study evaluates whether monitoring changes in exhaled carbon dioxide (End-Tidal CO2 or EtCO2) during a "Passive Leg Raising" (PLR) test can reliably predict fluid responsiveness in critically ill patients.

In the Intensive Care Unit (ICU), fluid management is a critical balance; while fluid is necessary for tissue perfusion, overload can lead to severe complications. Traditional static measurements (like central venous pressure) are often unreliable for guiding therapy. Dynamic tests like PLR are preferred as they simulate a fluid bolus reversibly by shifting blood from the legs to the heart.

Researchers will observe mechanically ventilated patients planned for fluid resuscitation. The study compares the accuracy of non-invasive EtCO2 changes during PLR against a reference standard "Mini Fluid Challenge" (100 mL fluid administration). Fluid responsiveness will be confirmed using echocardiographic measurements (LVOT-VTI) or arterial pressure changes. The goal is to validate EtCO2 as a practical, real-time tool for safe fluid management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fluid management is the cornerstone of hemodynamic stabilization in ICU patients with circulatory failure. However, distinguishing between patients who will benefit from fluid (responders) and those who will not is vital to prevent the high mortality associated with inappropriate fluid administration.Static parameters (e.g., CVP, MAP) fail to reliably predict fluid responsiveness. Dynamic parameters are superior but have limitations, such as dependence on regular heart rhythm and specific ventilation settings. Consequently, interest has shifted toward non-invasive surrogates for cardiac output, such as End-Tidal CO2 (EtCO2), which tracks pulmonary blood flow changes under constant ventilation. This study investigates whether Delta EtCO2 during a PLR maneuver can accurately predict the response to a fluid challenge. The primary objective is to determine the diagnostic accuracy of Delta EtCO2 during PLR. Its predictive value will be validated against the hemodynamic response to a Mini Fluid Challenge (MFC), serving as the reference method. This prospective, single-center, observational cohort study includes adult patients in the ICU receiving mechanical ventilation who require fluid resuscitation.

Passive Leg Raising (PLR) Test: The patient starts in a semi-recumbent position (45°). They are then moved to a supine position with legs raised to 45° without manual handling to avoid sympathetic stimulation. This auto-transfuses blood from the lower body to the central circulation, increasing preload.

Mini Fluid Challenge (MFC): Following PLR, 100 mL of crystalloid fluid is infused intravenously over approximately 1 minute.

Definition of Fluid Responsiveness (Reference Standard): An increase in Left Ventricular Outflow Tract Velocity Time Integral (LVOT-VTI) of \>10% on echocardiography. If cardiac output/VTI cannot be assessed, responsiveness is defined as a Systolic Arterial Pressure increase of \> 4%, a Pulse Pressure variation decrease of \> 2%, or a Mean Arterial Pressure increase of \> 15%.

The sample size was calculated using G\*Power 3.1 software based on a pilot study of 6 patients. In the pilot study, Delta EtCO2 values were found to be 3.5±2.1 mmHg in the fluid responder group and 2.1±1.1 mmHg in the non-responder group. Based on these findings, with an effect size (Cohen's d) of 0.72, an alpha error level of 0.05, and a targeted power (1-beta) of 0.80, the required sample size was calculated. Accounting for a potential 10% attrition rate, the study is planned to be conducted with a total of 68 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Circulatory Failure Critical Illness Hypovolemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Fluid Responsiveness Passive Leg Raising End-Tidal CO2 Mini Fluid Challenge Mechanical Ventilation Intensive Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluid Responders

Patients who demonstrate a significant hemodynamic improvement following the Mini Fluid Challenge (MFC. Defined as an increase in Left Ventricular Outflow Tract Velocity Time Integral (LVOT-VTI) of \>10%. If VTI unavailable, increase in Systolic Arterial Pressure \> 4%, Pulse Pressure variation decrease \> 2%, or Mean Arterial Pressure increase \> 15%.

No interventions assigned to this group

Fluid Non-Responders

Patients who do not demonstrate a significant hemodynamic improvement following the Mini Fluid Challenge (MFC). Defined as an increase in LVOT-VTI of \< 10% (or failure to meet the alternative blood pressure criteria).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older.
* Patients who have been followed in the intensive care unit (ICU) with mechanical ventilation support for at least 24 hours.
* Patients for whom a mini fluid challenge (MFC) is clinically planned by the intensive care team.
* Patients for whom informed consent has been obtained from first-degree relatives or a legal representative.

Exclusion Criteria

* Patients younger than 18 years of age.
* Pregnant patients.
* Patients without consent from first-degree relatives or a legal representative.
* Patients with known deep vein thrombosis (DVT) in the leg veins (risk of embolism during leg raising).
* Patients with pathologies that may cause increased intracranial pressure (e.g., intracranial mass, hemorrhage).
* Patients with uncontrolled hypertension.
* Patients with severe cardiac disease (e.g., right heart failure, pulmonary hypertension, advanced valvular pathology).
* Patients with carbon dioxide (CO2) retention.
* Patients who have undergone hip surgery or hip replacement surgery where Passive Leg Raising (PLR) cannot be performed.
* Patients with spontaneous breathing.
* Patients with a probability of high intra-abdominal pressure.
* Patients who cannot lie in a supine position.
* Patients with current peripheral oxygen saturation (SpO2) \< 88%.
* Patients on mechanical ventilation requiring pressure support \> 16 mmHg or PEEP \> 10 mmHg.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Izmir Katip Celebi University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmet Salih Tüzen, MD

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Murat Aksun, M.D.

Role: PRINCIPAL_INVESTIGATOR

Izmir Katip Celebi University Atatürk Training and Research Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Izmir Katip Celebi University Atatürk Training and Research Hospital

Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Murat Aksun, M.D.

Role: CONTACT

Phone: +90 552 363 16 14

Email: [email protected]

Ahmet Salih Tüzen, M.D.

Role: CONTACT

Phone: +90 535 391 55 77

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Deniz Özen Öz, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-SAEK-0807

Identifier Type: -

Identifier Source: org_study_id